Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings, Inc. Class A (RANI)
:RANI
Holding RANI?
Track your performance easily
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.24 - $8.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)465.36K
Market Cap
$73.51M
Enterprise Value$67.77M
Total Cash (Recent Filing)$16.54M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Mar 19, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,311,543
10 Day Avg. Volume323,619
30 Day Avg. Volume465,364
Standard Deviation0.30
R-Squared0.00067
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$12.25Price Target Upside828.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Advances in Biotherapeutics Market
PremiumMarket News
3 Penny Stocks to Watch Now, 10/15/24
PremiumStock Analysis & Ideas
Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Innovative Drug DeliveryRani Therapeutics has developed the RaniPill capsule, which is a novel, proprietary, and patented platform technology intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral administration.
Market PotentialRani’s pipeline in psoriasis, psoriatic arthritis, hypoparathyroidism, and obesity presents an opportunity to tap into a global biologics market that reached $516B in 2022 and is expected to grow to $856B by 2031.
Strategic PartnershipsThe partnership positions Rani in the GLP-1/obesity space, with the potential for significant economic benefits and the ability to conduct further development with other GLP-1 drugs.
Bears Say
Clinical TrialsNegative clinical readouts with other candidates pose a risk to the stock's performance.
Market PerformanceSlower-than-projected market uptake for key products may impact revenue expectations.
Regulatory ApprovalsFailure to achieve approvals for key pipeline projects could hinder future growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.74% Insiders
2.75% Mutual Funds
12.38% Other Institutional Investors
53.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $1.24 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $73.51M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Mar 19, 2025 which is in 60 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.05.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.27.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 33,311,543 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -4.858%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (828.03% Upside)
$12.25 (828.03% Upside)
Insider Transactions
Sold Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.17%
12-Months-Change
Fundamentals
Return on Equity
-272.52%
Trailing 12-Months
Asset Growth
-38.19%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trials, partnerships, and market potential, particularly in the obesity sector, while also acknowledging financial challenges and plans for raising additional capital.Read More>---
RANI Stock 12 Month Forecast
Average Price Target
$12.25
▲(828.03% Upside)
Technical Analysis
ALX Oncology Holdings
―
BioAtla
―
Caribou Biosciences
―
Immatics
―
Oric Pharmaceuticals
―
Best Analysts Covering RANI
1 Year
1 Year Success Rate
3/18 ratings generated profit
1 Year Average Return
-37.31%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -37.31% per trade.
---